NCT01188733View on ClinicalTrials.gov

Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 30, 1998

Primary Completion Date

July 31, 2000

Study Completion Date

December 31, 2000

Conditions
CirrhosisPortal HypertensionEsophageal Varices
Interventions
DRUG

Long acting octreotide 10mg

Comparison of different doses

DRUG

Long acting Octreotide 30mg

Comparison of drug doses

DRUG

Saline

Comparison of drug doses

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER